S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:VRDN

Viridian Therapeutics Stock Forecast, Price & News

$17.04
+0.02 (+0.12%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$15.93
▼
$17.51
50-Day Range
$17.02
▼
$21.50
52-Week Range
$10.44
▼
$22.46
Volume
29,498 shs
Average Volume
67,656 shs
Market Capitalization
$370.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.13
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive VRDN News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Viridian Therapeutics logo

About Viridian Therapeutics

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Headlines

Biocept (NASDAQ:BIOC) & Viridian Therapeutics (NASDAQ:VRDN) Head to Head Comparison
January 13, 2022 |  americanbankingnews.com
Viridian Therapeutics Submits Investigational New Drug Application For VRDN-002 To FDA
January 4, 2022 |  benzinga.com
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
January 4, 2022 |  finance.yahoo.com
Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
December 20, 2021 |  finance.yahoo.com
Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
December 20, 2021 |  finance.yahoo.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2021 |  finance.yahoo.com
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)
November 15, 2021 |  finance.yahoo.com
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Misses Revenue Estimates
November 5, 2021 |  finance.yahoo.com
Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
November 4, 2021 |  finance.yahoo.com
Viridian Therapeutics to Present at Upcoming Investor Conferences
November 3, 2021 |  finance.yahoo.com
BRIEF-Viridian Therapeutics Inc Submits Investigational New Drug Application For VRDN-001 To The U.S. Food And Drug Administration
October 14, 2021 |  msn.com
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration
October 14, 2021 |  finance.yahoo.com
Viridian Therapeutics, Inc. (VRDN)
October 14, 2021 |  realmoney.thestreet.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRDN
Previous Symbol
CUSIP
N/A
CIK
1590750
Web
www.viridiantherapeutics.com
Phone
(617) 272-4600
Fax
760-537-4101
Employees
27
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.05 million
Price / Sales
352.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($15.55) per share
Price / Book
-1.10

Profitability

EPS (Most Recent Fiscal Year)
($29.44)
Net Income
$-110.71 million
Net Margins
-5,037.78%
Pretax Margin
-5,037.78%
Return on Equity
N/A
Return on Assets
-48.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.20
Quick Ratio
15.20

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
21,722,000
Free Float
19,832,000
Market Cap
$370.14 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/25/2022
Next Earnings (Estimated)
3/24/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.65 out of 5 stars

Medical Sector

1000th out of 1,416 stocks

Medical Laboratories Industry

23rd out of 31 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Viridian Therapeutics (NASDAQ:VRDN) Frequently Asked Questions

Is Viridian Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Viridian Therapeutics stock.
View analyst ratings for Viridian Therapeutics or view top-rated stocks.

Are investors shorting Viridian Therapeutics?

Viridian Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totaling 332,000 shares, an increase of 43.9% from the December 15th total of 230,700 shares. Based on an average trading volume of 129,200 shares, the days-to-cover ratio is currently 2.6 days.
View Viridian Therapeutics' Short Interest.

When is Viridian Therapeutics' next earnings date?

Viridian Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Viridian Therapeutics.

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($1.25) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($1.25). The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $1 million.
View Viridian Therapeutics' earnings history.

What price target have analysts set for VRDN?

5 brokerages have issued 1-year price objectives for Viridian Therapeutics' shares. Their forecasts range from $32.00 to $40.00. On average, they expect Viridian Therapeutics' share price to reach $36.00 in the next year. This suggests a possible upside of 111.5% from the stock's current price.
View analysts' price targets for Viridian Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Viridian Therapeutics' key executives?

Viridian Therapeutics' management team includes the following people:
  • Jonathan Violin, President, Chief Executive Officer & Director
  • Kristian Franz Humer, Chief Financial, Accounting & Business Officer
  • Vahe Bedian, Chief Scientist
  • Barrett Katz, Chief Medical Officer
  • Deepa Rajagopalan, Senior VP-New Product & Portfolio Development

What is Viridian Therapeutics' stock symbol?

Viridian Therapeutics trades on the NASDAQ under the ticker symbol "VRDN."

How do I buy shares of Viridian Therapeutics?

Shares of VRDN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viridian Therapeutics' stock price today?

One share of VRDN stock can currently be purchased for approximately $17.02.

How much money does Viridian Therapeutics make?

Viridian Therapeutics has a market capitalization of $369.71 million and generates $1.05 million in revenue each year. The company earns $-110.71 million in net income (profit) each year or ($29.44) on an earnings per share basis.

How many employees does Viridian Therapeutics have?

Viridian Therapeutics employs 27 workers across the globe.

What is Viridian Therapeutics' official website?

The official website for Viridian Therapeutics is www.viridiantherapeutics.com.

Where are Viridian Therapeutics' headquarters?

Viridian Therapeutics is headquartered at 6200 LOOKOUT ROAD, BOULDER CO, 80301.

How can I contact Viridian Therapeutics?

Viridian Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The company can be reached via phone at (617) 272-4600, via email at [email protected], or via fax at 760-537-4101.


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.